Clinical evaluation of recombinant factor IX

Area of Science:

• Hematology
• Pharmacology

Background:

• Hemophilia B is a genetic bleeding disorder caused by deficiency in factor IX.
• Recombinant factor IX (rFIX) offers a potential therapeutic alternative to plasma-derived products.

Purpose of the Study:

• To evaluate the pharmacokinetics, safety, and efficacy of rFIX in hemophilia B patients.
• To assess rFIX performance in managing bleeding episodes and surgical procedures.

Main Methods:

• A clinical trial involving 56 previously treated hemophilia B patients.
• Administration of rFIX for hemorrhages and during 13 surgical procedures.
• Pharmacokinetic comparison with a plasma-derived factor IX product.

Main Results:

• 80% of hemorrhages resolved with a single rFIX infusion; 87% of infusions yielded excellent/good responses.
• 97% of surgical responses were rated excellent/good, with expected blood loss.
• rFIX showed comparable half-life but statistically lower recovery (28% less) than a plasma-derived product.
• Adverse events and viral transmission were comparable to other factor IX products.

Conclusions:

• rFIX demonstrates favorable efficacy and safety for hemophilia B treatment, comparable to existing therapies.
• rFIX is effective in managing bleeding episodes and perioperative hemostasis.
• While recovery is lower than plasma-derived products, rFIX offers a viable therapeutic option.